analyses (Hazard Ratio 1.52 [1.17,1.97], p¼0.002). There was no significant association between PRU quintiles and mortality.
Careggi Hospital, Florence, Italy Background: In patients undergoing PCI for STEMI/NSTEMI, a loading dose (LD) of the new potent P2Y12 inhibitors, thanks to their early onset of platelet inhibition, can be administered immediately after the diagnostic coronary angiography. However, there are no data about the level of platelet inhibition they provide during and immediately after the PCI with this timing of administration. We sought to assess and compare the action of prasugrel, ticagrelor and clopidogrel during and immediately after the PCI for STEMI/NSTEMI when administered with this specific timing. Methods: Seventy-two patients with STEMI/NSTEMI undergoing urgent PCI with heparin monotherapy were randomized after the coronary angiogram to receive 60 mg prasugrel LD (n 24) or ticagrelor 180 mg (n 24) or clopidogrel 600 mg (n 24). Residual platelet reactivity was assessed with VerifyNow at baseline, 30 min and 120 min after the LD. A 24 h platelet reactivity assessment with Light Transmission Aggregometry (LTA) was also performed. Results: Platelet reactivity units (PRU) 30 min after the LD were 305 (AE70), 286 (AE59) and 280 (AE70) in the prasugrel, ticagrelor and clopidogrel group, respectively (p¼ NS). PRU 120 min after the LD were 220 (AE100), 210 (AE88) and 163 (AE101), respectively (overall p 0.1). At 120 min PRU post hoc analysis only clopidogrel Vs ticagrelor were significantly different (p ¼ 0.03). Furthermore, high residual platelet reactivity (HRPR) (PRU > 240) was found in 52%, 28% and 58% of patient in the prasugrel, ticagrelor and clopidogrel group, respectively (p¼ 0.12). No case of HRPR (defined as LTA assessed residual platelet activity > 65%) were found in the prasugrel and ticagrelor group while 55% of patients showed HRPR in the clopidogrel group (p< 0.01). At multivariate analysis no independent predictors of HRPR at 120 min were found. Conclusions: None of the drugs studied achieved an effective platelet inhibition during the PCI when administered immediately after the coronary angiogram in patients with STEMI/NSTEMI. At 120 min only ticagrelor achieved a significantly higher inhibition of platelet reactivity when compared to clopidogrel. A high percentage of HRPR both at 30 min and 120 min was present in all groups.
TCT-155
The Background: Many patients with coronary artery disease receive concomitant treatment with clopidogrel and calcium channel blockers (CCB). Prior small studies have raised concerns regarding the effect of CCB on clopidogrel-related platelet reactivity and its clinical significance. We examined this relationship in the large scale Assessment of Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES) registry. Methods: A total of 8,583 patients had P2Y12 platelet reactivity testing using the VerifyNow point-of-care assay after successful, non-complicated PCI with DES implantation. All patients were treated with aspirin and clopidogrel, and were followed for 1 year. CCB were prescribed at the discretion of treating physicians. Results: At the time of the post-procedure P2Y12 test, 2437 (28.4%) pts were on CCB, and 6146 (71.6%) were not. Major baseline characteristics, P2Y12 results and 1-year follow-up events are summarized in the Table. The use of CCB was an independent predictor of higher platelet reactivity units (PRU) in a linear regression model (p<0.0001), and was independently associated with high platelet reactivity as defined as PRU >208 (OR 1.16, p¼0.014). At discharge, 1771 (20.6%) pts were prescribed CCB, and 6811 (79.4%) were not. In propensity-stratified proportional hazards regression models, the use of CCB was not independently associated with adverse outcomes. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM Conclusions: In patients on clopidogrel after DES, the concomitant administration of CCB was associated with reduced platelet inhibition and increased post discharge adverse events. However, CCB were not associated with adverse clinical events by multivariable analysis, suggesting confounding by comorbidities and presenting characteristics. Thus, CCB may be used as indicated in patients on clopidogrel after DES.
TCT-156
Impact Background: In prior studies non-smokers have been reported to have reduced clinical benefit of clopidogrel treatment as compared to smokers. This new "smoker's paradox" has been explained by the increase in the production of clopidogrel's active metabolite in smokers. We examined this relationship in the large scale Assessment of Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. Methods: Patients had P2Y12 platelet reactivity testing using the VerifyNow pointof-care assay after successful, non-complicated PCI with DES implantation. All patients were treated with aspirin and clopidogrel, and were followed for 1 year. Current smoking status was defined as active smoking within 1 month prior to enrollment. Results: Of the 8,583 patients enrolled, 1,939 (22.6%) pts were current smokers and 6,644 (77.4%) were not. Major baseline characteristics, P2Y12 results and 1-year events are summarized in the Table. By multivariable analysis, current smoking status was inversely associated with platelet reactivity (p¼0.0002). In propensity-stratified proportional hazards regression models, current smoking was independently associated with 1-year all-cause mortality (HR [95%CI Conclusions: Current smokers treated with clopidogrel after non-complicated PCI have greater levels of platelet inhibition compared with non-smokers. However, after adjustment for differences in baseline characteristics, smoking status was independently associated with mortality at 1 year. This analysis does not support the existence of clopidogrel-related "smoker's paradox". 
